The platform includes a set of cloud-connected injection devices. Under the deal, MedCrypt will initially offer software security QuiO's first two products such as Si One and Si Pen.

Si One is designed to be used for specialty drugs, while Si Pen for diabetes patients.

The technology's drug delivery sensors and automatically sending real-time dosing data ability can now be incorporated with MedCrypt's software and monitoring device usage for suspicious behavior.

In addition, the integration enables devices to properly sign and encrypt data communicated through QuiO's cloud platform called ConnectedRx.

QuiO co-founder and CEO Alexander Dahmani said: "It's critical that our bi-directional communication channel remains secure at all times, from both a privacy and safety standpoint.

"We're proud to be working with MedCrypt, because their technology has been successfully used to secure some of the highest-risk medical devices in the market and we want every available defense in today's evolving cybersecurity landscape."

MedCrypt co-founder and CEO Mike Kijewski said: "We are looking forward to making data security a priority in the product development process for QuiO and similarly-staged companies.”

QuiO is engaged in the development of smart injection devices and connected software to monitor patients taking injectable therapies.